ClinicalTrials.gg
Active, not recruitingNCT03632044Updated Jul 21, 2026

Evaluation of Trigeminal Nerve Blockade

A Phase 4 interventional study of Ropivacaine and Sham Comparator in Mouth Abnormalities, Cleft Palate and Birth Defect, sponsored by University of Florida. Active, not recruiting at 1 site in United States. Open to participants aged 3 Months to 5 Years. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by University of Florida · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
3 Months to 5 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Cleft Palate with a site in United States — 9 open to participants now, 11 under way, 1 of them phase 3. Cleft Palate · United States.

Planned enrollment
14th of 22
40 · median 47
Started
2018
with 1 other
Phase 4
2 of 31
1 open now
Primary completion
2027-05
later than 4 of 10 live
Registered
20th of 31
by date
Lead sponsor
3 of 31
University of Florida

Among the 31 studies in Cleft Palate with a site in United States, this one is the 14th largest by planned enrollment of the 22 interventional ones that give a count, is one of 2 that started in 2018, is one of 2 in phase 4, reaches primary completion later than 4 of the 10 other live ones, and was the 20th registered.

Cleft Palate

123 studies on the registry are indexed under Cleft Palate; 35 are open to participants now.

Browse Cleft Palate studies →

Open to participants now

9 of the 31 studies in Cleft Palate with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 21 Cleft Palate studies recruiting now, 3 (14%) set no upper age limit and 18 (86%) stop at 75 or younger; 20 take children under 18; 2 take healthy volunteers.

This study: 3 Months to 5 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Cleft Palate with a site in United States, or all of them as a file.
02

Study summary

Cleft palate repair requires high doses of opioids for pain control postop. An alternative approach is placement of nerve blocks in the pterygopalatine fossa bilaterally, blocking the maxillary nerve \& covering the entire midface. Application of bilateral suprazygomatic maxillary nerve blockade of the infraorbital nerve may provide effective analgesia for cleft lip repair, improving time to oral intake, pain control and time to hospital discharge.

Read the detailed description

Cleft palate is a common congenital anomaly for which surgical repair is indicated during early childhood. The surgical repair of cleft palate is very painful, and generally requires high doses of opioids for adequate pain control, placing children at risk for post-operative respiratory depression and airway obstruction. An alternative approach to post-operative analgesia for cleft palate repair is the placement of nerve blocks in the pterygopalatine fossa bilaterally, blocking the maxillary nerve and covering the entire mid-face. This randomized, double-blinded study will investigate the utility of maxillary nerve blockade in controlling post-operative pain, decreasing opioid requirements, improving post-operative oral food and drink intake, and decreasing hospital length-of-stay after cleft palate repair.

03

Conditions studied

  • Mouth Abnormalities
  • Cleft Palate
  • Birth Defect
04

Who can participate

Ages eligible
3 Months to 5 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient presenting for palatoplasty for cleft palate only.
  • Parent/guardian consents to participate
  • Normal oral food and water intake before surgery
  • No underlying chronic pain condition

Exclusion criteria

Exclusion Criteria:

  • Parent/guardian refuses to consent
  • Patient requires revision surgery on the palate
  • Patient requires surgery in addition to palatoplasty, including, but not limited to pharyngeal flap or soft palate lengthening procedures.
  • Any underlying chronic pain condition
  • Presence of any other factor which, at the discretion of any member of the study team, makes the patient a poor candidate for block placement.
  • Presence of any other factor which, at the discretion of any member of the study team, makes the patient a poor candidate for research participation.
  • History of Pierre Robin sequence
  • Planned or anticipated need for any type of artificial airway post-op
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Suprazygomatic maxillary nerve blockade

    A single injection into the pterygopalatine fossa bilaterally of 0.2% ropivacaine at a dose of 0.15 mL/kg (block) after the induction of general anesthesia.

    Drug: Ropivacaine

  • Sham comparator
    25 Gauge needle

    Subcutaneous placement of a 25 Gauge needle as a sham comparator after the induction of general anesthesia. Nothing will be injected.

    Other: Sham Comparator

Interventions

  • A single injection into the pterygopalatine fossa bilaterally of 0.2% ropivacaine at a dose of 0.15 mL/kg (block) after the induction of general anesthesia

    Also known as: Naropin

  • OtherSham Comparator

    The subcutaneous placement of a 25 Gauge needle as a sham control after the induction of general anesthesia. Nothing will be injected.

    Also known as: Control

06

What researchers measure

Primary outcomes

  1. Change in time to oral intake following palatoplasty for cleft palate

    Application of bilateral suprazygomatic maxillary nerve blockade of the infraorbital nerve to provide effective analgesia for cleft lip repair, improving time to oral intake after surgery.

    Time frame: Change from baseline (post-op) and through study completion, an average of 96 hours.

Secondary outcomes

  1. Change in amount of opioids following palatoplasty for cleft palate

    Application of bilateral suprazygomatic maxillary nerve blockade of the infraorbital nerve to provide effective analgesia for cleft lip repair, improving pain control after surgery.

    Time frame: Change from baseline (post-op) and through study completion, an average of 96 hours.

  2. Change in length of hospitalization following palatoplasty for cleft palate

    Application of bilateral suprazygomatic maxillary nerve blockade of the infraorbital nerve to provide effective analgesia for cleft lip repair, improving time to hospital discharge after surgery.

    Time frame: Change from baseline (post-op) and through study completion, an average of 96 hours.

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2018 (actual). Primary completion is estimated for May 2027, 102 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2018
First posted
Aug 15, 2018
StartActual
Nov 20, 2018
Primary completionEst.
May 31, 2027
CompletionEst.
Oct 30, 2027
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03632044
Responsible party
Sponsor
First posted
Aug 15, 2018
Start date
Nov 20, 2018
Primary completion
May 31, 2027 (estimated)
Completion
Oct 30, 2027 (estimated)
Last update
Jul 21, 2026

Study contacts

Cameron R Smith, MD, PhD
principal investigator · University of Florida

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ropivacaine

Start the discussion